Perivascular Stem Cells Diminish Muscle Atrophy Following Massive Rotator Cuff Tears in a Small Animal Model

Eliasberg, Claire D. MD; Dar, Ayelet PhD; Jensen, Andrew R. MD, MBE; Murray, Iain R. MD, PhD; Hardy, Winters R. PhD; Kowalski, Tomasz J. MD, PhD; Garagozlo, Cameron A. BA; Natsuhara, Kyle M. MD; Khan, Adam Z. MD; McBride, Owen J. BS; Cha, Peter I. BA; Kelley, Benjamin V. BA; Evseenko, Denis MD, PhD; Feeley, Brian T. MD; McAllister, David R. MD; Péault, Bruno PhD; Petrigliano, Frank A. MD

Journal of Bone & Joint Surgery - American Volume:
doi: 10.2106/JBJS.16.00645
Scientific Articles
Disclosures
Abstract

Background: Rotator cuff tears are a common cause of shoulder pain and often necessitate operative repair. Muscle atrophy, fibrosis, and fatty infiltration can develop after rotator cuff tears, which may compromise surgical outcomes. This study investigated the regenerative potential of 2 human adipose-derived progenitor cell lineages in a murine model of massive rotator cuff tears.

Methods: Ninety immunodeficient mice were used (15 groups of 6 mice). Mice were assigned to 1 of 3 surgical procedures: sham, supraspinatus and infraspinatus tendon transection (TT), or TT and denervation via suprascapular nerve transection (TT + DN). Perivascular stem cells (PSCs) were harvested from human lipoaspirate and sorted using fluorescence-activated cell sorting into pericytes (CD146+ CD34 CD45 CD31) and adventitial cells (CD146 CD34+ CD45 CD31). Mice received no injection, injection with saline solution, or injection with pericytes or adventitial cells either at the time of the index procedure (“prophylactic”) or at 2 weeks following the index surgery (“therapeutic”). Muscles were harvested 6 weeks following the index procedure. Wet muscle weight, muscle fiber cross-sectional area, fibrosis, and fatty infiltration were analyzed.

Results: PSC treatment after TT (prophylactic or therapeutic injections) and after TT + DN (therapeutic injections) resulted in less muscle weight loss and greater muscle fiber cross-sectional area than was demonstrated for controls (p < 0.05). The TT + DN groups treated with pericytes at either time point or with adventitial cells at 2 weeks postoperatively had less fibrosis than the TT + DN controls. There was less fatty infiltration in the TT groups treated with pericytes at either time point or with adventitial cells at the time of surgery compared with controls.

Conclusions: Our findings demonstrated significantly less muscle atrophy in the groups treated with PSCs compared with controls. This suggests that the use of PSCs may have a role in the prevention of muscle atrophy without leading to increased fibrosis or fatty infiltration.

Clinical Relevance: Improved muscle quality in the setting of rotator cuff tears may increase the success rates of surgical repair and lead to superior clinical outcomes.

Author Information

1Hospital for Special Surgery, New York, NY

2University of California, Los Angeles, Los Angeles, California

3University of Edinburgh, Edinburgh, United Kingdom

4University of California, Davis, Davis, California

5Washington University, St. Louis, Missouri

6University of Southern California, Los Angeles, California

7University of California, San Francisco, San Francisco, California

E-mail address for C.D. Eliasberg: eliasbergc@hss.edu

Article Outline

Rotator cuff tears are common shoulder injuries that often result in pain, disability, and diminished quality of life. Rotator cuff repair is the most common shoulder surgery in the United States, with >75,000 procedures performed annually1.

Massive rotator cuff tears account for 10% to 40% of all rotator cuff injuries2. These injuries are associated with poor clinical outcomes, including decreased range of motion, strength, and patient satisfaction3. Despite advances in surgical technique, reported repair failure rates range from 11% to as high as 94%4-7. Degenerative muscle changes, including atrophy, fibrosis, and fatty infiltration, can develop after massive rotator cuff tears and compromise surgical repair. Fibroadipogenic degeneration and atrophy decrease compliance of the musculotendinous unit8, lead to increased tension at the repair site9, and may contribute to repair failure and poor clinical outcomes3,6,8,10-12.

Several animal models have been used to characterize the etiology of muscle degeneration following rotator cuff tears13-16. Liu et al. developed a mouse model demonstrating consistent muscle atrophy, fibrosis, and fatty infiltration following transection of the supraspinatus and infraspinatus tendons (TT), denervation via suprascapular nerve transection (DN), and a combined procedure (TT + DN)15. These findings suggest that this small animal model demonstrates pathological changes similar to those observed in human rotator cuff tears.

Human perivascular stem cells (PSCs), a source of resident mesenchymal stem cells (MSCs), have demonstrated robust myogenic potential in other models of muscle injury17-19. In the current study, we evaluated 2 adipose-derived PSC populations—pericytes residing in small blood vessels and adventitial cells residing in large blood vessels—as potential regenerative therapies to reduce the fibroadipogenic changes seen following massive rotator cuff tears17. PSCs are highly myogenic, both in culture and in vivo18,20, and have also demonstrated the ability to recover functional deficits following muscle injury17,21,22. These multipotent cells have distinct translational advantages. They can be obtained in high numbers from adipose tissue and isolated via cell surface markers, potentially without the need for culture, providing expanded availability for autologous regenerative therapies. In addition to their inherent regenerative potential, PSCs may act in a trophic fashion by secreting paracrine growth factors and cytokines, which enhance native stem cell recruitment and myogenic differentiation23. While the myogenic potential of pericytes is well documented, the potential of adventitial cells to differentiate into skeletal myofibers is still under investigation17-19,24. However, the proliferative advantage of adventitial cells over pericytes in long-term cultures makes them better therapeutic candidates17, warranting further investigation into their myogenic potential17-19,24.

This study investigated the regenerative potential of 2 human adipose-derived progenitor cell lineages in a murine model of massive rotator cuff tears. We specifically studied these cells in the absence of rotator cuff repair to assess their potential as a perioperative adjuvant. Regenerative potential was assessed by measuring changes in muscle atrophy, fibrosis, and fatty infiltration following the index surgery as well as cell survival. We hypothesized that (1) the administration of PSCs would diminish muscle atrophy and fatty infiltration, (2) pericytes would have a more robust regenerative effect than adventitial cells, and (3) this therapeutic effect would be greater when cells were delivered in the presence of early fibroadipogenic muscle changes.

Back to Top | Article Outline

Materials and Methods

Mice

Immunodeficient mice (JAX 001303; Jackson Laboratories) were used. Mice were 10 weeks old at the date of the procedure and were housed under specific pathogen-free conditions in the Animal Barrier Facility of the University of California, Los Angeles. All experiments were approved by the Institutional Animal Care and Use Committee of the University of California, Los Angeles.

Back to Top | Article Outline
Rotator Cuff Injury Model

Rotator cuff injury was induced in sex-matched mice. Animals were assigned to 1 of 3 surgical procedures: sham, TT, or TT + DN. Procedures were performed utilizing methods previously described15.

The mice that underwent TT or TT + DN received no injection, injection with saline solution, or injection with pericytes or adventitial cells either at the time of the index procedure (as a “prophylactic” injection) or at 2 weeks following the index surgery (as a “therapeutic” injection). The mice that underwent the sham procedure received either an injection of pericytes or adventitial cells at the time of surgery or saline solution injection (Table I). Surgeries were performed on the animals’ right shoulders, with the contralateral shoulders left intact as controls. All mice received buprenorphine injections for postoperative pain management.

Power analysis was performed using an estimated 15% difference in muscle weight loss between control groups and cell-injection groups, on the basis of our previous experience utilizing this model and these PSCs15, with β = 0.80 and α = 0.05. We determined that 6 mice per group would be sufficient to demonstrate significant differences in muscle atrophy between the control and treatment groups.

Back to Top | Article Outline
Cell Culture

PSCs were isolated from human white adipose tissue (WAT)18. These tissues were obtained from cosmetic procedures and de-identified of any patient-specific information prior to their use, rendering them institutional review board-exempt. Pericytes and adventitial cells were harvested from WAT using methods previously described18. Briefly, bloody tumescent tissue was removed from lipoaspirate samples via centrifugation. Adipose tissue was digested using Dulbecco’s Modified Eagle Medium (Gibco), 1× penicillin-streptomycin-amphotericin B (Anti-Anti [antibiotic-antimycotic]; Invitrogen), and collagenase type II (Sigma). Cell pellets were separated from mature adipocytes and resuspended in an erythrocyte lysis buffer. Using fluorescence-activated cell sorting (FACS), PSCs were divided into pericytes (CD146+ CD34 CD45 CD31) and adventitial cells (CD146 CD34+ CD45 CD31), as previously described19. The following commercial antibodies were used for FACS: CD146-FITC (AbD Serotec), CD31-PE (BD Pharmingen), CD45-APC-H7 (BD Biosciences), and CD34-APC (BD Biosciences). These purified cells were expanded in vitro and cultured in endothelial cell growth medium (Lonza). The medium was exchanged every 3 to 4 days. All injections were performed using passage-5 cells.

Back to Top | Article Outline
PSC Injections

For PSC injections, 5 × 105 cells were suspended in 30 μL of phosphate-buffered saline (PBS) solution and delivered in 2 equal aliquots into 2 locations (distal and proximal) in the supraspinatus muscle using a 29-gauge insulin syringe. The injections were administered either at the time of surgery (“prophylactic” injection) or at 2 weeks following the index procedure (“therapeutic” injection) (Fig. 1). For therapeutic injections, the mice were anesthetized, a skin incision was made, and the trapezius muscle was separated to allow for visualization of the supraspinatus muscle during cell injections.

Back to Top | Article Outline
Wet Muscle Weight

Both supraspinatus (SS) muscles were harvested from each animal 6 weeks following the index procedure. Muscle atrophy was assessed by measuring the percent difference in wet supraspinatus muscle weight—right (SSR) versus left (SSL)—for each animal. The percent change in wet muscle weight was calculated using the following equation: ([SSR – SSL]/SSL) × 100. Mean wet muscle weight was calculated for each experimental group.

Back to Top | Article Outline
Histology

Fresh tissue specimens were frozen by immersion in cooled isopentane and embedded in Tissue-Plus OCT (optimal cutting temperature) freezing medium (Fisher Scientific). Sections were cut at 10-μm thickness on a cryostat (Microm) and fixed with 50% acetone. Hematoxylin and eosin (H & E) (Fisher Scientific), oil red O (ORO) (Sigma), and picrosirius red (PSR) (Polysciences) staining was completed according to manufacturer instructions. Slides were mounted using Cytoseal XYL (Fisher Scientific) or Aqua-Mount (Thermo Scientific Shandon) mounting medium and observed on a bright field microscope (Axio Imager; Zeiss).

Histomorphometric analyses of H & E, PSR, and ORO-stained sections were performed using ImageJ (National Institutes of Health). For all histological analyses, cross-sections from the mid-belly of the supraspinatus muscle were used. To calculate muscle fiber cross-sectional area, random regions of interest were selected using customized macros. All muscle fibers within each region of interest were measured and averaged for each sample. The area fraction of collagen was measured by dividing the area of PSR staining by the entire sample area. Similarly, the area fraction of fat was measured by dividing the area of ORO staining by the entire sample area.

Back to Top | Article Outline
In Vivo Imaging

Luciferase-expressing human PSCs were established using lentiviral infection with MSCV-luciferase-RFP-TK virus (murine stem cell virus-luciferase-red fluorescent protein-thymidine kinase virus) (System Biosciences) to enable in vivo vital and longitudinal cell tracking. Prior to injection, luciferase-expressing cells were removed from the culture dish and co-labeled with the cell tracker CM-Dil (Molecular Probes) according to the manufacturer instructions. Cells were injected 2 weeks following the sham, TT, or TT + DN procedures. At various intervals post-implantation, mice were anesthetized and received intraperitoneal injection of luciferin (30 mg/kg). Bioluminescence was recorded using the IVIS Lumina II imaging system (PerkinElmer). Data were analyzed with Living Image software (version 4.5.2; PerkinElmer). Rabbit anti-human and mouse α-smooth muscle actin (α-SMA) (Abcam) and goat anti-rabbit-Alexa-488 (Molecular Probes) antibodies were used for immunohistochemistry. Fluorescence imaging was performed using an Axio Imager 2 microscope (Zeiss).

Back to Top | Article Outline
Statistical Analysis

Student t tests were used to evaluate differences in the mean wet muscle weight, area fraction of collagen, and area fraction of fat. Paired Kruskal-Wallis tests were used to calculate differences in muscle fiber cross-sectional area. All histological analyses were performed in a blinded fashion by 2 independent observers. Two-way, random-effects, interclass correlation coefficients (ICCs) with absolute agreement were determined for each histological quantification method. Differences between groups were evaluated using a significance level of 0.05. All statistical analyses were performed using Stata (version 13; StataCorp).

Back to Top | Article Outline

Results

Wet Muscle Weight

The mice in the TT groups that were treated with either prophylactic or therapeutic PSCs had significantly less wet weight loss at the final 6-week evaluation than did the TT controls (groups VII and VIII in Table I) (p < 0.05) (Fig. 2). The TT + DN groups treated with therapeutic injections (groups IV and VI) also had significantly less weight loss than their respective controls (groups I and II) (p < 0.05); however, the TT + DN groups treated with prophylactic injections (groups III and V) demonstrated no significant differences in weight loss compared with controls (groups I and II).

Back to Top | Article Outline
Muscle Fiber Cross-Sectional Area

The TT + DN groups treated with PSCs (groups III, IV, V, and VI) had significantly greater mean muscle fiber cross-sectional areas than their respective controls (groups I and II) (p < 0.05). Similarly, TT groups treated with PSCs (groups IX, X, XI, and XII) had significantly greater mean muscle fiber cross-sectional areas than their respective controls (groups VII and VIII) (p < 0.05) (Table II). Two independent observers calculated the muscle fiber cross-sectional area measurements; the ICC was 0.886 (95% confidence interval [CI], 0.828 to 0.924). Representative histological images from each group are displayed in Figures 3, 4, and 5.

Back to Top | Article Outline
Fibrosis

As measured by the mean area fraction of collagen, there was no significant difference in fibrosis among any of the TT groups. However, the TT + DN group treated with therapeutic adventitial cells (group IV) and the TT + DN groups treated with either prophylactic or therapeutic pericytes (groups V and VI) had significantly less fibrosis than their respective controls (groups I and II) (p < 0.05) (Fig. 6). Two independent observers performed the analysis; the ICC was 0.868 (95% CI, 0.706 to 0.930).

Back to Top | Article Outline
Fatty Infiltration

There was significantly less fatty infiltration in the TT groups treated with pericytes at either time point (groups XI and XII) or with prophylactic adventitial cells (group IX) when compared with their respective controls (groups VII and VIII) (p < 0.05). There were no significant differences in fatty infiltration between the cell injection groups and controls for either TT + DN or sham procedures (Fig. 7). Two independent observers performed the analysis; the ICC was 0.859 (95% CI, 0.618 to 0.932).

Back to Top | Article Outline
In Vivo Imaging

Representative bioluminescence images can be found in Figure 8-A. Bioluminescent signal was observed up to 4 weeks following PSC injection for all surgical groups, indicating the persistence of injected cells over this interval. Transplanted CM-Dil prelabeled PSCs are shown aligning with myofibers in Figure 8-B. The absence of α-SMA expression demonstrates that CM-Dil PSCs did not adopt a fibrotic phenotype despite the environmental adipofibrotic cues (Fig. 9).

Back to Top | Article Outline

Discussion

Modest progress has been made in utilizing regenerative adjuvants to improve rotator cuff healing and repair. To date, most investigative efforts have focused on improving healing at the bone-tendon interface and have yielded mixed results25-30. Less attention has been focused on the roles of muscle atrophy and fatty infiltration and their effect on the healing of rotator cuff tears. Given the efficacy of MSCs in regenerating injured tissue in other musculoskeletal applications, we hypothesized that perivascular progenitor cells could be utilized in the treatment of massive rotator cuff tears to diminish fibroadipogenic degeneration.

Utilizing a mouse model of massive rotator cuff tears, our study demonstrated that there was significantly less muscle atrophy in the groups treated with PSCs compared with the respective controls for both TT and TT + DN. These findings were supported by both wet muscle weight and muscle fiber cross-sectional area data.

The reduction in muscle atrophy observed with PSC treatment could be explained by 2 phenomena. PSCs may have a regenerative effect in which they fuse to, or differentiate into, native myofibers. This would be consistent with recent evidence suggesting that progenitor cells can contribute to myogenesis either by differentiating and fusing to growing myofibers or by entering the satellite cell pool22. At the 2-week time point in the current study, injected PSCs were found to align with native myofibers of the injured rotator cuff. Furthermore, our co-localization immunohistochemistry studies suggested that CM-Dil PSCs did not adopt a fibrotic phenotype, given the lack of expression of the myofibroblast marker α-SMA. Lastly, RNA-sequencing analysis demonstrated that pericytes and adventitial cells express myogenesis-related genes such as FGF2 (fibroblast growth factor 2), FST (follistatin), HGF (hepatocyte growth factor), IGF1 (insulin-like growth factor 1), and IL6 (interleukin 6) (see Appendix).

PSCs may also have a prolonged trophic effect on the native muscle via growth-factor expression. The ability of these cell populations to produce growth factors known to enhance tissue repair, such as heparin-binding epidermal growth factor (HB-EGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF)-BB, and vascular endothelial growth factor (VEGF), has been previously described23. Additionally, we found that secretion of VEGF, a growth factor known to promote angiogenesis and enhance MSC survival31,32, was high in cultured PSCs (see Appendix). Therefore, one or multiple processes may contribute to the clinical and histological differences in muscle atrophy observed in the current study.

Additionally, we found that PSC injections did not contribute to increased fibrosis in the setting of rotator cuff tears. However, the TT + DN groups that received either prophylactic or therapeutic pericyte injections or therapeutic adventitial cells had less fibrosis than TT + DN controls. The absence of increased fibrosis is promising, as a potential complication with these injections is that the cells may follow a profibrotic pathway, leading to adverse outcomes33-35. However, the decreased fibrosis seen in the TT + DN groups suggests that the cells may inhibit these profibrotic processes. This is consistent with the results reported by Chen et al., utilizing pericytes in a mouse model of myocardial infarction21.

Some of our histomorphometric results differed between the prophylactic and therapeutic treatment groups. Specifically, wet muscle weight change for the therapeutic groups following TT + DN was significantly less than for the respective controls, while the prophylactic injection groups demonstrated no such change. These findings may be attributable to an altered microenvironment and increases in myogenic transcription factor expression following rotator cuff tears36. A previous study by Frey et al. demonstrated increased expression of the myogenic transcription factor Myf-5 in the weeks following rotator cuff tenotomy in an ovine model37, which could explain the more robust clinical response observed in our therapeutic treatment groups, by which the cells were delivered into a biological milieu primed to drive myogenic differentiation.

Finally, there was a modest though significant difference in fatty infiltration in the TT groups treated with PSCs compared with controls, but no differences in fatty infiltration among the TT + DN groups. The similarities in fatty infiltration among the TT + DN groups may be secondary to denervation, which has been shown to play an important role in the development of fatty infiltration14,38,39. Furthermore, while there was significantly less fatty infiltration in the TT groups, given the small absolute difference (∼1%), it is likely not clinically relevant. Nonetheless, our results suggest that the use of PSCs may contribute to the prevention of muscle atrophy by aiding in the maintenance of muscle bulk without leading to increased fibroadipogenesis.

There were limitations to our study, many of which are inherent to using animal models to replicate human pathology. Suprascapular nerve transection was required to produce massive fat infiltrate, consistent with the original model developed by Liu et al.15. While there are data demonstrating that suprascapular nerve palsy may contribute to fatty infiltration following rotator cuff injury40,41, complete transection of the suprascapular nerve rarely occurs in human disease. Thus, while several aspects of human rotator cuff pathology are recreated in this small animal model, it may not completely mirror the human disease process. While mice of similar age, weight, and sex were used in this study, normal variation in rotator cuff muscle weight may be present in this strain. We attempted to control for this variation by comparing the treatment effect in the experimental limb with values noted for the untreated limb in the same animal.

Additionally, our study utilized a mature, but relatively young, population of mice. While rotator cuff tears are more commonly observed in an older human population, mice of this age were chosen because young mice demonstrated degenerative muscle changes similar to those seen in humans in this previously validated model15. While the number of native progenitor cells has been shown to decrease with age42,43, the myogenic potential and intrinsic functionality of satellite cells appear to be age-independent44-46. However, additional studies in aged animals are necessary to further characterize the role of PSCs in reducing muscle atrophy.

Finally, to validate the use of human PSCs preclinically, we utilized immunodeficient mice as PSC recipients. While the complex interplay of immune responses following rotator cuff injury has not been fully elucidated47-50, it is possible that this model does not mirror the muscle changes that would be seen in an immunocompetent model. However, a study by Brzóska et al. suggested that skeletal muscle regeneration in severe combined immunodeficient [SCID] mice is similar to that in immunocompetent mice with respect to muscle fiber size, fibrosis, and fatty infiltration51. Nonetheless, additional studies investigating the role of inflammatory responses following rotator cuff tears would augment our understanding of fibroadipogenesis.

In summary, we demonstrated that 2 PSC populations—adventitial cells and pericytes—exhibit regenerative potential in the setting of massive rotator cuff tears. Currently, there is great heterogeneity among methods of stem cell procurement, methods of application, and cell types utilized in rotator cuff repair studies. Ultimately, the goal is to characterize and standardize a cell population with the greatest ease and efficacy of clinical translation. PSCs provide the distinct advantages of having an abundant and readily available source in adipose tissue and of being easily isolated via cell surface markers. Further investigation is necessary to fully elucidate the regenerative capacity of these cells and to better characterize their mechanism of action. Nonetheless, these results, which demonstrate the regenerative potential of these cells in a model of massive rotator cuff tears with no significant increases in fatty infiltration or fibrosis, suggest that they may serve as a viable perioperative therapy.

Back to Top | Article Outline

Appendix Cited Here...

Tables detailing the PSC transcript expression of growth factors related to muscle cell growth and/or differentiation and PSC secretion of VEGF as demonstrated in RNA-sequencing analysis are available with the online version of this article as a data supplement at jbjs.org (http://links.lww.com/JBJS/A10).

Investigation performed at the University of California, Los Angeles, Los Angeles, California

Disclosure: This work was supported by the Orthopaedic Research and Education Foundation and the California Institute of Regenerative Medicine. On the Disclosure of Potential Conflicts of Interest forms, which are provided with the online version of the article, one or more of the authors checked “yes” to indicate that the author had a relevant financial relationship in the biomedical arena outside the submitted work and “yes” to indicate that the author had a patent and/or copyright, planned, pending, or issued, broadly relevant to this work (http://links.lww.com/JBJS/A9).

Back to Top | Article Outline

References

1. Vitale MA, Vitale MG, Zivin JG, Braman JP, Bigliani LU, Flatow EL. Rotator cuff repair: an analysis of utility scores and cost-effectiveness. J Shoulder Elbow Surg. 2007 ;16(2):181–7.
2. Bedi A, Maak T, Walsh C, Rodeo SA, Grande D, Dines DM, Dines JS. Cytokines in rotator cuff degeneration and repair. J Shoulder Elbow Surg. 2012 ;21(2):218–27.
3. Cofield RH, Parvizi J, Hoffmeyer PJ, Lanzer WL, Ilstrup DM, Rowland CM. Surgical repair of chronic rotator cuff tears. A prospective long-term study. J Bone Joint Surg Am. 2001 ;83(1):71–7.
4. Boileau P, Brassart N, Watkinson DJ, Carles M, Hatzidakis AM, Krishnan SG. Arthroscopic repair of full-thickness tears of the supraspinatus: does the tendon really heal? J Bone Joint Surg Am. 2005 ;87(6):1229–40.
5. Galatz LM, Ball CM, Teefey SA, Middleton WD, Yamaguchi K. The outcome and repair integrity of completely arthroscopically repaired large and massive rotator cuff tears. J Bone Joint Surg Am. 2004 ;86(2):219–24.
6. Gerber C, Fuchs B, Hodler J. The results of repair of massive tears of the rotator cuff. J Bone Joint Surg Am. 2000 ;82(4):505–15.
7. Levy O, Venkateswaran B, Even T, Ravenscroft M, Copeland S. Mid-term clinical and sonographic outcome of arthroscopic repair of the rotator cuff. J Bone Joint Surg Br. 2008 ;90(10):1341–7.
8. Chaudhury S, Dines JS, Delos D, Warren RF, Voigt C, Rodeo SA. Role of fatty infiltration in the pathophysiology and outcomes of rotator cuff tears. Arthritis Care Res (Hoboken). 2012 ;64(1):76–82.
9. Gerber C, Meyer DC, Schneeberger AG, Hoppeler H, von Rechenberg B. Effect of tendon release and delayed repair on the structure of the muscles of the rotator cuff: an experimental study in sheep. J Bone Joint Surg Am. 2004 ;86(9):1973–82.
10. Burkhart SS, Barth JR, Richards DP, Zlatkin MB, Larsen M. Arthroscopic repair of massive rotator cuff tears with stage 3 and 4 fatty degeneration. Arthroscopy. 2007 ;23(4):347–54.
11. Gartsman GM. Massive, irreparable tears of the rotator cuff. Results of operative debridement and subacromial decompression. J Bone Joint Surg Am. 1997 ;79(5):715–21.
12. Gladstone JN, Bishop JY, Lo IK, Flatow EL. Fatty infiltration and atrophy of the rotator cuff do not improve after rotator cuff repair and correlate with poor functional outcome. Am J Sports Med. 2007 ;35(5):719–28. Epub 2007 Mar 2.
13. Gupta R, Lee TQ. Contributions of the different rabbit models to our understanding of rotator cuff pathology. J Shoulder Elbow Surg. 2007 ;16(5)(Suppl):S149–57.
14. Kim HM, Galatz LM, Lim C, Havlioglu N, Thomopoulos S. The effect of tear size and nerve injury on rotator cuff muscle fatty degeneration in a rodent animal model. J Shoulder Elbow Surg. 2012 ;21(7):847–58. Epub 2011 Aug 10.
15. Liu X, Laron D, Natsuhara K, Manzano G, Kim HT, Feeley BT. A mouse model of massive rotator cuff tears. J Bone Joint Surg Am. 2012 ;94(7):e41.
16. Rowshan K, Hadley S, Pham K, Caiozzo V, Lee TQ, Gupta R. Development of fatty atrophy after neurologic and rotator cuff injuries in an animal model of rotator cuff pathology. J Bone Joint Surg Am. 2010 ;92(13):2270–8.
17. Crisan M, Corselli M, Chen WC, Péault B. Perivascular cells for regenerative medicine. J Cell Mol Med. 2012 ;16(12):2851–60.
18. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badylak S, Buhring HJ, Giacobino JP, Lazzari L, Huard J, Péault B. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008 ;3(3):301–13.
19. Park TS, Gavina M, Chen CW, Sun B, Teng PN, Huard J, Deasy BM, Zimmerlin L, Péault B. Placental perivascular cells for human muscle regeneration. Stem Cells Dev. 2011 ;20(3):451–63. Epub 2010 Nov 30.
20. Crisan M, Chen CW, Corselli M, Andriolo G, Lazzari L, Péault B. Perivascular multipotent progenitor cells in human organs. Ann N Y Acad Sci. 2009 ;1176:118–23.
21. Chen CW, Okada M, Proto JD, Gao X, Sekiya N, Beckman SA, Corselli M, Crisan M, Saparov A, Tobita K, Péault B, Huard J. Human pericytes for ischemic heart repair. Stem Cells. 2013 ;31(2):305–16.
22. Dellavalle A, Maroli G, Covarello D, Azzoni E, Innocenzi A, Perani L, Antonini S, Sambasivan R, Brunelli S, Tajbakhsh S, Cossu G. Pericytes resident in postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells. Nat Commun. 2011 ;2:499.
23. Chen CW, Montelatici E, Crisan M, Corselli M, Huard J, Lazzari L, Péault B. Perivascular multi-lineage progenitor cells in human organs: regenerative units, cytokine sources or both? Cytokine Growth Factor Rev. 2009 ;20(5-6):429–34.
24. Chen WC, Péault B, Huard J. Regenerative translation of human blood-vessel-derived MSC precursors. Stem Cells Int. 2015;2015:375187. Epub 2015 Jul 26.
25. Gulotta LV, Kovacevic D, Ehteshami JR, Dagher E, Packer JD, Rodeo SA. Application of bone marrow-derived mesenchymal stem cells in a rotator cuff repair model. Am J Sports Med. 2009 ;37(11):2126–33. Epub 2009 Aug 14.
26. Isaac C, Gharaibeh B, Witt M, Wright VJ, Huard J. Biologic approaches to enhance rotator cuff healing after injury. J Shoulder Elbow Surg. 2012 ;21(2):181–90.
27. Omi R, Gingery A, Steinmann SP, Amadio PC, An KN, Zhao C. Rotator cuff repair augmentation in a rat model that combines a multilayer xenograft tendon scaffold with bone marrow stromal cells. J Shoulder Elbow Surg. 2016 ;25(3):469–77. Epub 2015 Sep 19.
28. Rodeo SA. Biologic augmentation of rotator cuff tendon repair. J Shoulder Elbow Surg. 2007 ;16(5)(Suppl):S191–7. Epub 2007 Jun 15.
29. Tokunaga T, Shukunami C, Okamoto N, Taniwaki T, Oka K, Sakamoto H, Ide J, Mizuta H, Hiraki Y. FGF-2 Stimulates the growth of tenogenic progenitor cells to facilitate the generation of tenomodulin-positive tenocytes in a rat rotator cuff healing model. Am J Sports Med. 2015 ;43(10):2411–22. Epub 2015 Aug 26.
30. Valencia Mora M, Ruiz Ibán MA, Díaz Heredia J, Barco Laakso R, Cuéllar R, García Arranz M. Stem cell therapy in the management of shoulder rotator cuff disorders. World J Stem Cells. 2015 ;7(4):691–9.
31. Pons J, Huang Y, Arakawa-Hoyt J, Washko D, Takagawa J, Ye J, Grossman W, Su H. VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun. 2008 ;376(2):419–22. Epub 2008 Sep 18.
32. Rodrigues M, Griffith LG, Wells A. Growth factor regulation of proliferation and survival of multipotential stromal cells. Stem Cell Res Ther. 2010 ;1(4):32.
33. Kang JR, Gupta R. Mechanisms of fatty degeneration in massive rotator cuff tears. J Shoulder Elbow Surg. 2012 ;21(2):175–80.
34. Murray IR, West CC, Hardy WR, James AW, Park TS, Nguyen A, Tawonsawatruk T, Lazzari L, Soo C, Péault B. Natural history of mesenchymal stem cells, from vessel walls to culture vessels. Cell Mol Life Sci. 2014 ;71(8):1353–74. Epub 2013 Oct 25.
35. Stenmark KR, Davie N, Frid M, Gerasimovskaya E, Das M. Role of the adventitia in pulmonary vascular remodeling. Physiology (Bethesda). 2006 ;21:134–45.
36. Perry RL, Rudnick MA. Molecular mechanisms regulating myogenic determination and differentiation. Front Biosci. 2000 ;5:D750–67.
37. Frey E, Regenfelder F, Sussmann P, Zumstein M, Gerber C, Born W, Fuchs B. Adipogenic and myogenic gene expression in rotator cuff muscle of the sheep after tendon tear. J Orthop Res. 2009 ;27(4):504–9.
38. Liu X, Manzano G, Kim HT, Feeley BT. A rat model of massive rotator cuff tears. J Orthop Res. 2011 ;29(4):588–95. Epub 2010 Oct 14.
39. Shah AA, Butler RB, Sung SY, Wells JH, Higgins LD, Warner JJ. Clinical outcomes of suprascapular nerve decompression. J Shoulder Elbow Surg. 2011 ;20(6):975–82. Epub 2011 Feb 1.
40. Albritton MJ, Graham RD, Richards RS 2nd, Basamania CJ. An anatomic study of the effects on the suprascapular nerve due to retraction of the supraspinatus muscle after a rotator cuff tear. J Shoulder Elbow Surg. 2003 ;12(5):497–500.
41. Costouros JG, Porramatikul M, Lie DT, Warner JJ. Reversal of suprascapular neuropathy following arthroscopic repair of massive supraspinatus and infraspinatus rotator cuff tears. Arthroscopy. 2007 ;23(11):1152–61.
42. Brack AS, Bildsoe H, Hughes SM. Evidence that satellite cell decrement contributes to preferential decline in nuclear number from large fibres during murine age-related muscle atrophy. J Cell Sci. 2005 ;118(Pt 20):4813–21.
43. Machida S, Narusawa M. The roles of satellite cells and hematopoietic stem cells in impaired regeneration of skeletal muscle in old rats. Ann N Y Acad Sci. 2006 ;1067:349–53.
44. Marg A, Escobar H, Gloy S, Kufeld M, Zacher J, Spuler A, Birchmeier C, Izsvák Z, Spuler S. Human satellite cells have regenerative capacity and are genetically manipulable. J Clin Invest. 2014 ;124(10):4257–65. Epub 2014 Aug 26.
45. Carlson BM, Faulkner JA. Muscle transplantation between young and old rats: age of host determines recovery. Am J Physiol. 1989 ;256(6 Pt 1):C1262–6.
46. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 2005 ;433(7027):760–4.
47. Manning CN, Martel C, Sakiyama-Elbert SE, Silva MJ, Shah S, Gelberman RH, Thomopoulos S. Adipose-derived mesenchymal stromal cells modulate tendon fibroblast responses to macrophage-induced inflammation in vitro. Stem Cell Res Ther. 2015 ;6:74.
48. Nho SJ, Yadav H, Shindle MK, Macgillivray JD. Rotator cuff degeneration: etiology and pathogenesis. Am J Sports Med. 2008 ;36(5):987–93. Epub 2008 Apr 15.
49. Oak NR, Gumucio JP, Flood MD, Saripalli AL, Davis ME, Harning JA, Lynch EB, Roche SM, Bedi A, Mendias CL. Inhibition of 5-LOX, COX-1, and COX-2 increases tendon healing and reduces muscle fibrosis and lipid accumulation after rotator cuff repair. Am J Sports Med. 2014 ;42(12):2860–8. Epub 2014 Sep 22.
50. Rooney SI, Baskin R, Torino DJ, Vafa RP, Khandekar PS, Kuntz AF, Soslowsky LJ. Ibuprofen differentially affects supraspinatus muscle and tendon adaptations to exercise in a rat model. Am J Sports Med. 2016 ;44(9):2237–45. Epub 2016 Jun 8.
51. Brzóska E, Grabowska I, Hoser G, Stremińska W, Wasilewska D, Machaj EK, Pojda Z, Moraczewski J, Kawiak J. Participation of stem cells from human cord blood in skeletal muscle regeneration of SCID mice. Exp Hematol. 2006 ;34(9):1262–70.

Supplemental Digital Content

Back to Top | Article Outline
Copyright 2017 by The Journal of Bone and Joint Surgery, Incorporated